Astellas Engineered Small Molecules US Inc. has identified poly(ADP-ribose) polymerase (PARP) inhibitors, particularly PARP-1 (ARTD1), reported to be useful for the treatment of neuronal injury.
Synthetic lethality specialist Tessellate Bio NV has closed its first deal, agreeing to a €500 million-plus (US$570 million) research and license agreement with Boehringer Ingelheim GmbH, to develop small molecules targeting tumors that depend on alternative lengthening of telomeres (ALT) for their growth.
With the closing of its $350.7 million series D, Eikon Therapeutics Inc. has notched two financial high marks for the still young year. The funding is the biggest venture capital round of 2025 and it’s also the first series D.
Elevar Therapeutics Inc. will license Relay Therapeutics Inc.’s “NDA-ready” bile duct cancer therapy, lirafugratinib (RLY-4008), through a potential $500 million deal as Elevar, an HLB Co. Ltd. subsidiary, seeks to diversify its oncology portfolio following the U.S. FDA rejection of its liver cancer drug candidate in May.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed phthalazinone or quinazolinone derivatives acting as poly(ADP-ribose) polymerase (PARP) inhibitors reported to be useful for the treatment of cancer.
Researchers have developed and tested a taurultam-derived oxathiazine compound, GP-2250, for the potential treatment of ovarian cancer. Taurolidine, a substance derived from the amino acid taurine, has been shown to have antiproliferative and antineoplastic activity in vitro and in vivo against various cancer types. GP-2250 was tested in vitro in several ovarian cancer cell lines, as well as in vivo as a monotherapy and in combination with standard-of-care drugs and PARP inhibitors.
Researchers from the Johns Hopkins University School of Medicine have hypothesized that LP-184 could synergize with the PARP inhibitor rucaparib, which avoids DNA repairing in tumor cells, for the treatment of atypical teratoid rhabdoid tumor.
Researchers from Federation University Australia and affiliated organizations have reported data from a study that aimed to assess the therapeutic efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in a large animal model of pulmonary fibrosis.
Achieving proof of concept and a substantial clinical benefit with its PARP inhibitor stenoparib in advanced recurrent ovarian cancer, Allarity Therapeutics Inc. stopped a phase II trial and is preparing for a registrational study for what is now the company’s only internal drug candidate.
Ariceum Therapeutics GmbH has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial (CITADEL-123) of 123I-ATT-001, its iodine-123 labeled PARP inhibitor, in patients with recurrent glioblastoma. The study is expected to begin in the U.K. in June of 2024.
